Fen Xia, MD, PhD

Research Program: Cancer Biology Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Radiation Oncology

Cancer Research Interest

• Research Interest Statement: I am a radiation oncologist specializing in tumors in central nerve system. My Research focuses on elucidating the mechanisms regulating the signaling pathways in response to DNA damage and the mechanism for repair of chromosomal double-strand breaks (DSB) that arise during physiological DNA metabolism and after radiation therapy or chemotherapy. Our research aims to understand the impact of deregulated DSB repair on carcinogenesis, tumor resistance, and normal tissue injury during cancer treatment. With the understanding of DNA repair process and its crosstalk with intracellular metabolism, and extracellular microenvironment, we hope to develop novel avenues for both cancer prevention and personalized cancer treatment

Contact Information

• Email Address: FXIA@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• NIH/Nat. Cancer Institute – 1R01CA247947
  “The novel role of Sirtuin 2 in regulation of transcription-associated DNA damage repair”
  Principal Investigator
  04/01/20 – 03/31/25

Publications

• Patel MA, Bimali M, Li C, [et al., including Xia F]. The effect of anticonvulsants on survival among patients with GBM brain tumors undergoing radiation: A SEER-Medicare analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2022 106:32-36. PMID: 36265362. PMCID: PMC9896587.
• Nissen C, Ying J, Newkirk M, [et al., including Xia F]. An Analysis of Risk Factors for Radiation Necrosis Following Cranial Radiation. Cureus. 2022 14(9):e29268. PMID: 36133504. PMCID: PMC9482441.
• Shrestha N, Narayanasamy G, Kalantari F, [et al., including Xia F]. A phantom-based study and clinical implementation of Brainlab's treatment planning system for radiosurgical treatments of arteriovenous malformations. Biomedical physics & engineering express. 2022. PMID: 35856850.
• Deshazer G, Narayanasamy G, Bimali M, [et al., including Xia F]. A dosimetric comparative analysis of Brainlab elements and Eclipse RapidArc for spine SBRT treatment planning. Biomedical physics & engineering express. 2022 8(2). PMID: 35086071.
• Kesaria AZ, Bimali M, Patel M, [et al., including Xia F]. #Brachytherapy: Physicians As Influencers on Instagram. Cureus. 2022 14(2):e22524. PMID: 35371782. PMCID: PMC8953911.
• Acklin S, Sadhukhan R, Du W, [et al., including Xia F]. Nicotinamide riboside alleviates cisplatin-induced peripheral neuropathy via SIRT2 activation. Neuro-oncology advances. 2022 4(1):vdac101. PMID: 35875690. PMCID: PMC9297957.
• Kiss RC, Xia F, Acklin S. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment. International journal of molecular sciences. 2021 22(15). PMID: 34360968. PMCID: PMC8347825.
• Zhang M, Acklin S, Gillenwater J, [et al., including Xia F]. SIRT2 promotes murine melanoma progression through natural killer cell inhibition. Scientific reports. 2021 11(1):12988. PMID: 34155309. PMCID: PMC8217567.
• Acklin S, Xia F. The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment. International journal of molecular sciences. 2021 22(4). PMID: 33671279. PMCID: PMC7921932.
• Prabhu AV, Lee M, Galhardo E, [et al., including Xia F]. Pulsed reduced dose-rate radiotherapy for previously irradiated tumors in the brain and spine. Surgical neurology international. 2021 12:280. PMID: 34221611. PMCID: PMC8247706.
• Acklin S, Zhang M, Du W, [et al., including Xia F]. Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice. Scientific reports. 2020 10(1):14170. PMID: 32843706. PMCID: PMC7447787.
• Zhang M, Du W, Acklin S, [et al., including Xia F]. SIRT2 protects peripheral neurons from cisplatin-induced injury by enhancing nucleotide excision repair. The Journal of clinical investigation. 2020 130(6):2953-2965. PMID: 32134743. PMCID: PMC7260000.
• Miousse IR, Tobacyk J, Quick CM, [et al., including Xia F]. Reply to Flugge: the anti-metastatic potential of methionine restriction in melanoma. Carcinogenesis. 2020 41(3):390-391. PMID: 31140558. PMCID: PMC7221500.
• Zhao X, Du W, Zhang M, [et al., including Xia F]. Sirt2-associated transcriptome modifications in cisplatin-induced neuronal injury. BMC genomics. 2020 21(1):192. PMID: 32122297. PMCID: PMC7053098.
• Patel M, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell & bioscience. 2020 10:35. PMID: 32180937. PMCID: PMC7065339.
• Sizemore ST, Zhang M, Cho JH, [et al., including Xia F]. Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. Cell research. 2018 28(11):1090-1102. PMID: 30297868. PMCID: PMC6218445.
• Miousse IR, Tobacyk J, Quick CM, [et al., including Xia F]. Modulation of dietary methionine intake elicits potent, yet distinct, anticancer effects on primary versus metastatic tumors. Carcinogenesis. 2018 39(9):1117-1126. PMID: 29939201. PMCID: PMC6148987.
• Randhawa S, Viqar A, Strother J, [et al., including Xia F]. How Do Patients Rate Their Radiation Oncologists in the Modern Era: An Analysis of Vitals.com. Cureus. 2018 10(9):e3312. PMID: 30473945. PMCID: PMC6248776.
• Sizemore ST, Mohammad R, Sizemore GM, [et al., including Xia F]. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Molecular cancer research : MCR. 2018 16(7):1092-1102. PMID: 29592899. PMCID: PMC6713455.
• Zhang X, Rong Y, Morrill S, [et al., including Xia F]. Robust optimization in lung treatment plans accounting for geometric uncertainty. Journal of applied clinical medical physics. 2018 19(3):19-26. PMID: 29524301. PMCID: PMC5978970.
• Yu H, Harrison FE, Xia F. Altered DNA repair; an early pathogenic pathway in Alzheimer's disease and obesity. Scientific reports. 2018 8(1):5600. PMID: 29618789. PMCID: PMC5884847.
• Jiang J, Li Z, Li L, [et al., including Xia F]. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Investigational new drugs. 2017 35(3):251-259. PMID: 28111726.
• Arneson K, Mondschein J, Stavas M, [et al., including Xia F]. A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. Journal of neuro-oncology. 2017 133(2):435-442. PMID: 28488066.
• Abana CO, Bingham BS, Cho JH, [et al., including Xia F]. IL-6 variant is associated with metastasis in breast cancer patients. PloS one. 2017 12(7):e0181725. PMID: 28732081. PMCID: PMC5521838.